Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | ACHE | P22303 | 5/20 | 0.69 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.57 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609859 | 0.98 | ALDH1A1 (0.66) | ALDH1A1ACHEOPRL1CYP1A2CYP2D6 | |
| SCHEMBL11813176 | 0.90 | OPRL1 (0.65) | ALDH1A1ACHEOPRL1HSD11B1SMN1; SMN2 | |
| SCHEMBL18274478 | 0.87 | ALDH1A1 (0.62) | ALDH1A1ACHEOPRL1CYP1A2CYP2D6 | |
| SCHEMBL11612810 | 0.83 | OPRD1 (0.54) | ALDH1A1ACHEOPRL1CYP1A2CYP2D6 | |
| SCHEMBL5752267 | 0.81 | OPRD1 (0.59) | ALDH1A1ACHEOPRL1HSD11B1SMN1; SMN2 | |
| SCHEMBL15797283 | 0.81 | ALDH1A1 (0.70) | ALDH1A1ACHEOPRL1TSHRRAB9A | |
| SCHEMBL14593219 | 0.81 | CHRM2 (0.59) | ALDH1A1ACHEOPRL1CYP2D6CYP2C19 | |
| SCHEMBL11259596 | 0.81 | ALDH1A1 (0.65) | ALDH1A1ACHEOPRL1TSHRRAB9A | |
| SCHEMBL2781893 | 0.81 | ALDH1A1 (0.71) | ALDH1A1ACHEOPRL1CYP2D6CYP2C19 | |
| SCHEMBL1033178 | 0.81 | CYP1A2 (0.57) | ALDH1A1ACHECYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030049807-A1 | Micro-organism possessing enantioselective and regioselective nitrile hydratase/amidase activities | INSTITUTO BIOCHIMICO ITALIANO GIOVANNI LOREZINI S.P.A. (IT) | 2003-03-13 | — | — | US | claimed |
| EP-1291435-A2 | A micro-organism possessing enantioselective and regioselective nitrile hydratase/amidase activities | ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. (IT) | 2003-03-12 | — | — | EP | claimed |
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200308158-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
| EP-2598483-B1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9663496-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| CN-103201267-B | AMPK-activating heterocyclic compounds and methods of use thereof | 里格尔药品股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2016-08-11 | — | — | US | disclosed |
| EP-1981504-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV Remynd (BE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| EP-0920424-B1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20030049807-A1 | Micro-organism possessing enantioselective and regioselective nitrile hydratase/amidase activities | INSTITUTO BIOCHIMICO ITALIANO GIOVANNI LOREZINI S.P.A. (IT) | 2003-03-13 | — | — | US | disclosed |
| EP-1291435-A2 | A micro-organism possessing enantioselective and regioselective nitrile hydratase/amidase activities | ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. (IT) | 2003-03-12 | — | — | EP | disclosed |
| US-6194437-B1 | ANTIDEPRESSANTS; ANTICANCER AGENTS; GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-0920424-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998007718-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | ALDH1A1 807/4885ACHE 1651/4885OPRL1 3070/4885 |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | ALDH1A1 807/4885ACHE 1651/4885OPRL1 3070/4885 |
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, LIPC, PNLIP | ALDH1A1 800/4885ACHE 1002/4885OPRL1 1414/4885 |
| US-20200308158-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, LIPC, PNLIP | ALDH1A1 800/4885ACHE 1002/4885OPRL1 1414/4885 |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | ALDH1A1 807/4885ACHE 1651/4885OPRL1 3070/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | ALDH1A1 807/4885ACHE 1651/4885OPRL1 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.